1. Outcomes of Mitral Valve Regurgitation Management after Expert Multidisciplinary Valve Team Evaluation.
- Author
-
Welman, Myrthe J. M., Streukens, Sebastian A. F., Mephtah, Anass, Hoebers, Loes P., Vainer, Jindrich, Theunissen, Ralph, Heuts, Samuel, Maessen, Jos G., Segers, Patrique, Vernooy, Kevin, van 't Hof, Arnoud W. J., Sardari Nia, Peyman, and Vriesendorp, Pieter A.
- Subjects
MITRAL valve ,SURVIVAL rate ,WATCHFUL waiting ,SURVIVAL analysis (Biometry) ,DRUG therapy ,MITRAL valve insufficiency - Abstract
Background/Objectives: Mitral regurgitation (MR) affects millions worldwide, necessitating timely intervention. There are significant clinical challenges in the conservative management of MR, leaving a knowledge gap regarding the impact of multidisciplinary decision-making on treatment outcomes. This study aimed to provide insights into the impact of multidisciplinary decision-making on the survival outcomes of MR patients, focusing on conservative approaches. Methods: This study retrospectively analyzes 1365 patients evaluated by an expert multidisciplinary heart team (MDT) in a single center from 2015 to 2022. Treatments included surgery, catheter-based interventions, and conservative management. Propensity matching was utilized to compare surgery and conservative approaches. Results: Surgical intervention was associated with superior long-term survival outcomes compared to conservative and catheter-based treatments, particularly for degenerative MR (DMR). Survival rates of patients deemed by the MDT to have non-severe DMR were comparable to surgical patients (HR 1.07, 95% CI: 0.37–3.12, p = 0.90). However, non-severe functional MR (FMR) patients trended towards elevated mortality risk (HR 1.77, 95% CI: 0.94–3.31, p = 0.07). Pharmacological treatment for DMR was associated with significantly higher mortality compared to surgery (HR 8.0, 95% CI: 1.78–36.03, p = 0.001). Functional MR patients treated pharmacologically exhibited a non-significantly higher mortality risk compared to surgical intervention (HR 1.93, 95% CI: 0.77–4.77, p = 0.20). Conclusions: Survival analysis revealed significant benefits for surgical intervention, contrasting with elevated mortality risks associated with conservative management. "Watchful waiting" may be appropriate for non-severe DMR, while FMR may require closer monitoring. Further research is needed to assess the impact of regular follow-up or delayed surgery on survival rates, as pharmacological therapy has limited long-term efficacy for DMR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF